Enrico Piccinini | Senior Vice President, EU & International, Rare Diseases
Chiesi Group
Enrico has been the Head of Europe & International Rare Diseases, at the Chiesi Group since November 2019, leading a team fully dedicated to making value-adding treatments available for rare and ultra-rare diseases. He previously had a long tenure in Genzyme and SanofiGenzyme covering different sub-regional and regional/EMEA/EU roles in both functional areas and business ones. During the last seven years as General Manager of SanofiGenzyme Italy & Malta, he led his team through different launches and sustained business growth within Rare and other Specialty Care diseases. He is member of various Biotech/RD and Orphan Drugs groups and associations, and since 2022, he leads the Famindustria (Italy) RD national working group.
Appearances:
Pre-Congress Workshops - Tuesday 22nd October @ 14:00
WORKSHOP: Reducing the Burden of Rare Diseases Across The Patient Journey [OFFSITE]
People living with rare diseases face distinct and significant challenges that arise from the infrequency of their medical conditions, such as a long diagnostic journey, inadequate clinical management, and limited access to effective treatments. The burden of rare diseases on patients, their carers and families, healthcare systems, and society overall, deserves greater visibility and recognition. Addressing these societal challenges requires a multifaceted approach involving stakeholders across the healthcare system, government agencies, research institutions, industry, and patient advocacy organizations.
This discussion will examine the patient perspective and the burdens faced explore what is needed to speed up and improve the patient journey of Europeans living with rare diseases, with clear recommendations for health systems and policymakers.
The session will be broken into two parts:
Part 1 – The Patient Perspective: Patient experiences along the rare disease 'journey'
Part II – 'We all have a role' – multi-stakeholder solutions across the rare disease 'journey' from industry, R&D, AI, HTA and health systems.
Day 1 - Wednesday 23 October @ 16:40
Panel: EU General Pharmaceutical Legislation – Europe’s Biotech Innovation for Rare Diseases in the Balance?
On 24 January 2024, EuropaBio published a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem which concluded that the GPL would have significant impact on innovation for rare diseases in the future.
-What would be the expected impact of the GPL on biotech innovation and innovators for rare diseases?
-What improvements can be made to ensure a sustained flow and growth of biotech innovation for rare diseases?
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events